Sam Chun Dang Pharm. Co., Ltd
Financials
Valuation Metrics
Sam Chun Dang Pharm. Co., Ltd's Market Cap is ₩4.3T. At end of 2025 it was ₩5.5T. Ranked #107 of 2,405 in KR market (top 4%), #11 of 1,627 on KOSDAQ (top 0.7%), #8 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 3%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 4.30T KRW | KR#107/2,405 Sec#8/231 |
| Revenue | 259.90B KRW | KR#897/2,405 Sec#44/231 |
| Net Income | 25.47B KRW | KR#616/2,405 Sec#37/231 |
| Total Assets | 575.39B KRW | KR#705/2,405 Sec#38/231 |
| Net Assets | 400.79B KRW | KR#594/2,405 Sec#37/231 |
| Employees | 417 | KR#584/2,405 Sec#49/231 |
| Value | ||
| P/E | 168.88x | KR#1,519/2,405 Sec#103/231 |
| P/B | 10.73x | KR#2,361/2,405 Sec#214/231 |
| P/S | 16.55x | KR#2,316/2,405 Sec#182/231 |
| EV/EBITDA | 243.04x | KR#1,532/2,405 Sec#106/231 |
| FCF Yield | -0.84% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | 6.36% | KR#942/2,405 Sec#65/231 |
| ROA | 4.43% | KR#801/2,405 Sec#63/231 |
| Op. Margin | 6.83% | KR#741/2,405 Sec#61/231 |
| Revenue Growth | 20.83% | KR#530/2,405 Sec#50/231 |
| Financial Health | ||
| Debt Ratio | 43.57% | KR#856/2,405 Sec#100/231 |
| Total Debt | 74.15B KRW | KR#837/2,405 Sec#56/231 |
| FCF | -36.35B KRW | KR#2,012/2,405 Sec#197/231 |
| Cash | 63.02B KRW | KR#652/2,405 Sec#35/231 |
| Current Ratio | 2.21x | KR#787/2,405 Sec#93/231 |
| Net Debt/EBITDA | 0.63x | KR#694/2,405 Sec#43/231 |
| Dividend | ||
| Div. Yield | 0.03% | KR#1,378/2,405 Sec#86/231 |
| Div. Growth | -75.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -21.62% | KR#1,219/2,405 Sec#89/231 |
| 1M Return | -11.40% | KR#1,288/2,405 Sec#124/231 |
| From 52W High | -85.13% | KR#2,359/2,405 Sec#225/231 |
| 1Y MDD | -89.32% | KR#2,383/2,405 Sec#227/231 |
| Trading | ||
| Volume | 72,065 shares | KR#776/2,405 Sec#81/231 |
| Trading Value | 13.17B KRW | KR#163/2,405 Sec#12/231 |
| Foreign Own. | 4.77% | KR#896/2,405 Sec#80/231 |
| Per Share | ||
| EPS | 1,086 KRW | KR#695/2,405 Sec#46/231 |
| BPS | 17,086 KRW | KR#620/2,405 Sec#41/231 |
Company Info
Samchundang Pharm, established in 1943 and headquartered in Hwaseong-si, Gyeonggi-do, began as a pharmaceutical manufacturer and seller. By acquiring Optus Pharm in 2013, it became a leading specialized ophthalmic treatment company, producing prescription-based pharmaceuticals including antibiotics, circulatory disease treatments, digestive disease treatments, and eye drops. The company is actively expanding its global market presence by exporting finished pharmaceuticals to Vietnam, Hong Kong, and Singapore.